期刊文献+

慢性肾功能不全患者CYFRA21-1水平与肾功能指标的相关性分析 被引量:2

Correlation Between the Level of CYFRA21-1 and Renal Function Index in Patients with Chronic Renal Failure
下载PDF
导出
摘要 目的分析慢性肾功能不全患者血清中CYFRA21-1水平与肾功能有关指标的相关性,探讨CYFRA21-1在慢性肾功能不全患者血清中的表达及临床意义。方法选取在我院进行健康体检者50人作为健康对照组;选取在我院肾脏内科住院的慢性肾功能不全患者50人作为慢性肾功能不全组,本组中再根据是否进行透析分为透析组(29人)和未透析组(21人),每组均抽血检测血清中CYFRA21-1、Cys-C和肌酐的浓度,并进行相关性分析。结果慢性肾功能不全患者CYFRA21-1、Cys-C、肌酐水平均明显高于健康对照组(P<0.01);透析组与未透析组之间CYFRA21-1和Cys-C水平无显著差异(P>0.1);透析组CYFRA21-1与Cys-C水平呈正相关(r=0.61,P<0.05),与肌酐水平无相关性;未透析组CYFRA21-1与Cys-C(r=0.63,P<0.05)和肌酐(r=0.59,P<0.05)水平呈正相关。结论慢性肾功能不全患者CYFRA21-1水平较正常人明显升高,且与Cys-C水平有一定相关性,可能与肾小球滤过功能减退和肾脏的代谢异常有关。 Objective To analysis the correlation between the level of CYFRA21-1 and renal function index in patients with chronic renal failure and to discuss the expression of CYFRA21-1 and its clinical significance.Methods 50 patients with chronic renal failure and 50 healthy volunteers were involved in this study. The patients group divided into dialysis group( 29 cases) and non-dialysis group( 21 cases). The serum levels of CYFRA21-1,Cystatin-C and creatinine in patients and healthy controls were detected. Results The serum levels of CYFRA21-1,Cys-C and creatinine in patients with chronic renal failure were significantly higher than those in healthy controls( P 〈0. 01). There was no significant difference in CYFRA21-1 levels and Cys-C level between dialysis group and non-dialysis group( P〉 0. 1). The CYFRA21-1 level was positively correlated with Cys-C in dialysis group( r = 0. 61,P 〈0. 05),and no correlation with creatinine level. The CYFRA21-1 level was positively correlated with Cys-C level( r = 0. 63,P〈 0. 05) and creatinine( r = 0. 59,P 〈0. 05) in nondialysis group. Conclusion The serum CYFRA21-1 levels in chronic renal failure patients are significantly increased and positively correlated with Cys-C levels. This result may be relevant to reduced glomerular filtration function and abnormal renal metabolism.
出处 《标记免疫分析与临床》 CAS 2015年第11期1077-1079,共3页 Labeled Immunoassays and Clinical Medicine
基金 国家高技术研究发展计划(863计划)子课题项目(2011AA02A111)
关键词 慢性肾功能不全 CYFRA21-1 肾功能 半胱氨酸蛋白酶抑制剂C Chronic renal failure CYFRA21-1 Renal function Cystatin-C
  • 相关文献

参考文献12

  • 1[2]李璞.医用生物学[M].北京:人民卫生出版社,1994.44~45.
  • 2Moll R, Schiller D L, Franke W W. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression pattems. J Cell Biol. , 1990, 111 ( 2 ) : 567-580.
  • 3Dohmoto K, Hojo S, Fujita I, et al. Mechanism of the release of CYFRA21-1 in human lung cancer cell lines. Lung Cancer, 2007, 30(1) : 55.
  • 4Sheard MA, Vojet esek B, Simickova M, et al. Release of cytokeratin-18 and 19 fragments( TPS and CYFRA21-1 )into the extracellular space during apoptosis. J Cell Biochem, 2008, 5 (4) : 670.
  • 5Kashiwabara K, Kishi K, Nakamura H, et al. Mechanism of increased serum cytokertin 19 fragment levels in patients with diabetic nephropathy as a model of chronic renal failure. Intern Med, 1998,37( 11 ) :917-921.
  • 6Kosuke Kashiwabara, Hiroyuki Nakamura, Toshio Kiguchi, et al. Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases. Clinica Chimica Acta,1998,273( 1 ) :35-42.
  • 7Nakahama H,Tanaka Y,Fujita Y,et.al. CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients. Respirology,1998,3(3),207-210.
  • 8Helin I, Axenran M, Grubb A. Serum cystatin C as a determinant of glomerular filtration rate in children. Clin Nephml, 1998,49 (4) : 221-225.
  • 9Latcrza O F, Price C P, Scott M G. Cystation C: an improved estimator of glomcrular fihration rate. Clin Chem, 2002,48 ( 5 ) : 699-707.
  • 10罗倩,张珏,张斌,王依屹,陈建中.慢性肾脏疾病患者CYFRA21-1的变化和临床意义[J].放射免疫学杂志,2012,25(5):581-582. 被引量:9

二级参考文献26

  • 1高力丁,李兴.血半胱氨酸蛋白酶抑制剂C诊断肾功能损害的研究进展[J].医学综述,2004,10(11):693-695. 被引量:23
  • 2杭宏东,王可平,林洪丽,于长青,王陆,孟华.血清半胱氨酸蛋白酶抑制剂C在临床中的应用[J].中国综合临床,2006,22(10):906-908. 被引量:10
  • 3塚本雄介,万毅刚.国际肾脏病指南——改善全球性肾脏病预后[J].日本医学介绍,2007,28(6):274-276. 被引量:10
  • 4陈文彬,潘祥林.诊断学[M].7版.北京:人民卫生出版社,2008:380.
  • 5Mizuguchi S, Nishiyama N, Iwata T, etal. Clinical value of serum cytokeratin 19 fragment and sialyl Lewis x in non-small cell lung cancer[J]. Ann Thorac Surg, 2007, 83(1): 216 -221.
  • 6Xiaofang Y, Yue Z, Xialian X, et al. Serum tumour markers in patients with chronic kidney disease[J].Scand J Clin Lab Invest, 2007, 67(6): 661 -667.
  • 7National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Am J Kidney Dis, 2002, 39(2 Suppl 1): S1-S266. Comment in: AmJ Kidney Dis, 2008, 51(2): 346.
  • 8Sun SS, Hsieh JF, Tsai SC, etal. Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recur rence of squamous cell lung carcinoma[J]. Am J Clin Oncol, 2000, 23(3): 241-243.
  • 9KashiwabaraK, KishiK, NakamuraH, etal. Mechanism olincreased serum cytokeratin 19 fragment levels in patients with di abetic nephropathy as a model of chronic renal failure[J]. Intern Med, 1998, 37(11): 917-921.
  • 10Takeuchi S, Saitoh H, Yoshida K, etal. The clinical usefulness of urinary determinations of cytokeratin 19 fragment (CYFRA 21 1) in urothelial tumor[J]. Hinyokika Kiyo, 1995, 41(8): 589-592.

共引文献19

同被引文献16

引证文献2

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部